Loginov A S, Matiushin B N, Sukhareva G V, Tkachev V D
Ter Arkh. 1988;60(8):74-7.
Hepatotropic drugs were shown to decrease blood lipid peroxidation activity (LPO) in patients with chronic diffuse liver diseases. A positive time course of LPO indices was noted in the treatment of chronic active hepatitis and liver cirrhosis of moderate activity. Comparison of antioxidant features of the drugs were suggestive of a noticeable effect of trophopar and essential in patients with chronic active hepatitis, trophopar in patients with liver lipodystrophy, and drugs of a silimarina series in patients with liver cirrhosis. Under clinical conditions the effect of the drugs on LPO processes was less noticeable than in experiments in vitro. It is assumed that the pharmacological effect of the hepatotropic drugs is associated with their antioxidant activity.
亲肝药物可降低慢性弥漫性肝病患者的血脂过氧化活性(LPO)。在慢性活动性肝炎和中度活动性肝硬化的治疗中,LPO指标呈阳性时间进程。对这些药物抗氧化特性的比较表明,曲奥舒凡对慢性活动性肝炎患者有显著作用,对肝脂肪营养不良患者必不可少,而西利马林系列药物对肝硬化患者有显著作用。在临床条件下,这些药物对LPO过程的作用不如在体外实验中明显。据推测,亲肝药物的药理作用与其抗氧化活性有关。